Medical Outpatient and Hypertension Clinic, ESH Hypertension Centre of Excellence, University Hospital Basel.
Department of Pharmacology, University Hospital Basel, Basel.
J Hypertens. 2021 Jun 1;39(6):1246-1253. doi: 10.1097/HJH.0000000000002766.
Noninvasive thoracic bioimpedance by the HOTMAN System estimates hemodynamic modulators and expresses them as hemodynamic profiles. Aims of this analysis were to describe hemodynamic profiles among treatment-naive hypertensive patients compared with normotensive controls and to investigate whether a hemodynamic-guided choice of therapy improves blood pressure (BP) control within 4 weeks.
This exploratory post hoc analysis used data of a randomized parallel-group trial including 80 outpatients with newly diagnosed arterial hypertension (AHT), randomized to four antihypertensive first-line monotherapies, and 20 age-matched and sex-matched normotensive controls. Hemodynamic profiles were measured at baseline and after four weeks of treatment. On the basis of the hemodynamic profiles, the most appropriate pharmacological treatment was determined retrospectively and patients were categorised to have received concordant (ConTG) or discordant treatment (DisTG).
In the hypertensive group, hypervolemia with vasoconstriction was the predominant hemodynamic profile in 48% of patients and hypervolemia without vasoconstriction in 45%, compared with 15 and 50%, respectively, in the control group. After 4 weeks of treatment, the mean (±SD) 24-h BP was 129.9 (±11.0)/81.5 (±8.0) mmHg in the DisTG vs. 133.9 (±12.3)/84.0 (±9.1) mmHg in the ConTG (P = 0.158/0.222). The mean 24-h BP reductions were -9.7 (±10.1)/-5.0 (±6.2) mmHg in the DisTG and -12.4 (±14.8)/-6.9(±6.9) mmHg in the ConTG (P = 0.353/0.223). After 4 weeks of treatment, the BP control rate was 53.7% (43/80) among all, 55.7% (29/52) in the DisTG and 48% (12/25) in the ConTG (P = 0.628).
Our findings do not support the hypothesis that personalized treatment initiation based on hemodynamic profiles improves BP control in newly diagnosed hypertensive outpatients.
通过 HOTMAN 系统进行无创性胸部生物阻抗测量,可对血流动力学调节剂进行评估并以血流动力学图谱的形式呈现。本分析旨在描述未经治疗的高血压患者与血压正常的对照组之间的血流动力学图谱,并探讨血流动力学指导的治疗选择是否能在 4 周内改善血压(BP)控制。
这是一项随机平行分组试验的事后探索性分析,共纳入 80 例新诊断为高血压的门诊患者(AHT),随机分为四种一线降压单药治疗,同时纳入 20 名年龄和性别匹配的血压正常对照组。在基线和治疗 4 周后测量血流动力学图谱。根据血流动力学图谱,回顾性确定最合适的药物治疗方案,将患者分为接受一致性治疗(ConTG)或不一致性治疗(DisTG)。
在高血压组中,与对照组的 15%和 50%相比,48%的患者存在血管收缩性高血容量,45%的患者存在无血管收缩性高血容量,而对照组的相应比例分别为 15%和 50%。在治疗 4 周后,DisTG 组的平均(±SD)24 小时 BP 为 129.9(±11.0)/81.5(±8.0)mmHg,而 ConTG 组为 133.9(±12.3)/84.0(±9.1)mmHg(P=0.158/0.222)。DisTG 组 24 小时 BP 平均降低幅度为-9.7(±10.1)/-5.0(±6.2)mmHg,ConTG 组为-12.4(±14.8)/-6.9(±6.9)mmHg(P=0.353/0.223)。治疗 4 周后,所有患者的 BP 控制率为 53.7%(43/80),DisTG 组为 55.7%(29/52),ConTG 组为 48%(12/25)(P=0.628)。
我们的研究结果不支持基于血流动力学图谱启动个体化治疗可改善新诊断高血压门诊患者血压控制的假说。